中广核技：非动力核技术龙头迈向高端

Investment Rating - The report initiates coverage with a "Buy" rating for CGN Technology (000881.SZ) [12] Core Views - CGN Technology is recognized as the leading enterprise in non-power nuclear technology applications in China, part of the China General Nuclear Power Group's "6+1" industrial system [3][19] - The company is currently facing short-term pressure on its performance due to underwhelming new materials business and losses in its cultivation period businesses [22] - The nuclear technology application industry in China has significant growth potential, with the market expected to expand substantially in the coming years [27][28] Summary by Sections Company Overview - CGN Technology is the first stock in non-power nuclear technology and serves as a development platform for non-power nuclear technology applications in China [3][19] - The company focuses on high-performance modified engineering plastics and is a major supplier in various sectors including industrial electrical, automotive, and electronic industries [20] Financial Performance - In 2021, the company achieved a revenue of 79.99 billion yuan, with a year-on-year growth of 20.25%. However, revenues declined by 13.18% and 8.53% in 2022 and 2023 respectively, with a slight recovery in 2024 [22] - The company's net profit for 2023 and the first three quarters of 2024 is projected to be negative due to high costs and competitive pressures [22] New Materials Transition - CGN Technology is optimizing its new materials structure and transitioning towards high-end materials, with traditional product sales expected to grow by approximately 5.5% in the first half of 2024 [4] - The company has seen a significant increase in sales in the "three new" markets, with a year-on-year growth of about 51.8% [4] Accelerator Technology - CGN Technology is a leader in the electronic accelerator market, with a focus on high-energy applications. The company has introduced advanced proton therapy technology and is establishing a production base for proton therapy equipment [5][53] - The market for proton therapy systems in China is projected to be substantial, with a total market size estimated at around 30.7 billion yuan during the 14th Five-Year Plan period [5] Profitability Forecast - The company forecasts a net profit of -3.13 billion yuan in 2024, with a gradual recovery to 1.20 billion yuan in 2025 and 1.90 billion yuan in 2026 [12] - The expected earnings per share (EPS) for 2024, 2025, and 2026 are projected to be -0.33, 0.13, and 0.20 yuan respectively [12]